Urovant Sciences is gearing up for a March launch of its first FDA-approved drug, Gemtesa, a beta-3 adrenergic receptor agonist which treats overactive bladder (OAB). The OAB market basket is rather crowded, and Gemtesa will have to face off against Astellas Pharma’s leading Myrbetriq, which currently holds preferred status without utilization management restrictions for 45% of all covered lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 1/25/21